Biogen News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

21.03.19	Biogen, Eisai To Discontinue Phase 3 ENGAGE, EMERGE Trials Of Aducanumab (RTTNews)
21.03.19	Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease (GlobeNewswire)
12.03.19	Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm (GlobeNewswire)
04.03.19	Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology (GlobeNewswire)
28.02.19	Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy (GlobeNewswire)
25.02.19	Alkermes Announces NDA Filing Acceptance For Diroximel Fumarate - Quick Facts (RTTNews)
25.02.19	Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis (GlobeNewswire)
29.01.19	Biogen Q4 Results Top Estimates; Sees 2019 Results In Line With View (RTTNews)
04.01.19	Biogen, Skyhawk Announce Collaboration - Quick Facts (RTTNews)
04.01.19	Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets (GlobeNewswire)
04.01.19	Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions (GlobeNewswire)
03.01.19	First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis (GlobeNewswire)
17.12.18	Alkermes Submits NDA For Diroximel Fumarate - Quick Facts (RTTNews)
17.12.18	Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis (GlobeNewswire)
06.12.18	Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data (GlobeNewswire)
29.11.18	International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product (GlobeNewswire)
26.10.18	Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD) (GlobeNewswire)
25.10.18	Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference (GlobeNewswire)
23.10.18	Biogen Q3 Profit Rises, Results Beat View - Quick Facts (RTTNews)
23.10.18	UCB, Biogen: Dapirolizumab Pegol Phase 2b Study Fails To Meet Primary Endpoint (RTTNews)
23.10.18	UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus (GlobeNewswire)
18.10.18	Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting (GlobeNewswire)
17.10.18	IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union (GlobeNewswire)
11.10.18	Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis (GlobeNewswire)
06.10.18	New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy (GlobeNewswire)
03.10.18	Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS) (GlobeNewswire)
02.10.18	Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care (GlobeNewswire)
04.09.18	Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction (GlobeNewswire)
28.08.18	Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab (GlobeNewswire)
25.07.18	Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018 (GlobeNewswire)
25.07.18	Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018 (GlobeNewswire)
24.07.18	Biogen Updates 2018 Financial Guidance - Quick Facts (RTTNews)
23.07.18	Applied Genetic Technologies Earns $10 Mln In Milestone Payment - Quick Facts (RTTNews)
21.07.18	Week Ahead In Pharmaceuticals - 14 Stocks To Watch (LCI, INSY, TBPH...) (RTTNews)
18.07.18	Data to be Presented From Biogen's Alzheimer's Disease Clinical Development Portfolio at the 2018 Alzheimer's Association International Conference (AAIC) (GlobeNewswire)
06.07.18	BIIB One Step Closer, MBVX To Be Delisted, RGLS In The Red On Pink Slip Woes (RTTNews)
06.07.18	Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months (GlobeNewswire)
03.07.18	Remember When Was The Last Time A New Alzheimer's Drug Was Approved? (RTTNews)
28.06.18	Biogen Exercises Option to Increase Ownership in Samsung Bioepis (GlobeNewswire)
13.06.18	Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference (GlobeNewswire)
07.06.18	Biogen Reaches Option Agreement To Buy TMS' Phase 2 Asset For Acute Stroke (RTTNews)
07.06.18	Biogen Enters Exclusive Option Agreement to Acquire TMS' Phase 2 Asset for Acute Stroke (GlobeNewswire)
06.06.18	Alkermes Receives License Payment From Biogen - Quick Facts (RTTNews)
06.06.18	BIIB's Alzheimer's Drug Scores Well, EXAS Heads Higher, VXRT Down But Not Out (RTTNews)
05.06.18	Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases (PR Newswire)
05.06.18	Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer's Disease At 18-Months (PR Newswire)
31.05.18	Biogen Appoints Daniel Karp as EVP, Corporate Development (GlobeNewswire)
01.05.18	Biogen To Reduce Royalty Rates On Aducanumab; To Pay $50 Mln To Neurimmune (RTTNews)
24.04.18	Biogen Inc. Q1 adjusted earnings Beat Estimates (RTTNews)
24.04.18	Biogen Reports Quarterly Revenues of $3.1 Billion (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	510.80	3.25 %	K V
UBS Group	30.02	2.18 %	K V
Logitech Intl	80.66	1.87 %	K V
Zurich Insur Gr	536.80	1.40 %	K V
Swiss Re	134.10	1.36 %	K V
Roche Hldg G	264.50	0.42 %	K V
Novartis	90.42	0.34 %	K V
Alcon	75.90	0.26 %	K V
CieFinRichemont	139.65	-0.39 %	K V
Nestle	73.72	-0.59 %	K V

mehr

15:58		Zuversicht in Europa: Euro STOXX 50 präsentiert sich nachmittags fester
15:58		Starker Wochentag in Frankfurt: LUS-DAX nachmittags mit Gewinnen
15:58		Zuversicht in Frankfurt: DAX steigt am Mittwochnachmittag
15:52		Investment-Tipp Sartorius vz-Aktie: Bernstein Research bewertet Anteilsschein in neuer Analyse
12:50		Bayer-Aktie aber freundlich: Bayer kassiert nächste PCB-Niederlage in USA - Warten auf höchstes Staatsgericht
12:26		Freundlicher Handel in Europa: Anleger lassen Euro STOXX 50 mittags steigen
12:26		Handel in Frankfurt: LUS-DAX mittags mit grünem Vorzeichen
12:26		Freundlicher Handel: TecDAX bewegt sich mittags im Plus